FDA Approvals and Rejections: GSK's Lynavoy, Knight Therapeutics' MINJUVI, Novartis' Cosentyx, Myriad Genetics' MyChoice CDx, and Aldeyra Therapeutics' Dry Eye Drug

GSK's Lynavoy received FDA approval for cholestatic pruritus in PBC, while Knight Therapeutics gained Brazil approval for an additional MINJUVI indication. Novartis' Cosentyx won FDA approval for pediatric hidradenitis suppurativa, and Myriad Genetics received FDA clearance for its MyChoice CDx ovarian cancer test. Aldreya Therapeutics' dry eye drug was rejected again by the FDA.